SEC Filing Summary: Disc Medicine, Inc. (IRON)
Business Context and Reporting Period
This Form 8-K, dated August 7, 2025, reports on Disc Medicine, Inc.'s financial results for the second quarter ended June 30, 2025. The filing serves as a current report to announce these results and provide a corporate update, with the detailed press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided filing text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the press release (Exhibit 99.1) but are not explicitly stated in the body of this 8-K document.
Material Changes
The filing text does not provide specific data regarding material changes versus the prior comparable period. Investors must refer to the attached press release for comparative financial analysis.
Guidance, Outlook, and Risks
Management provided a corporate update alongside the financial results, though specific guidance, outlook figures, or detailed risk factors are not enumerated in this summary text. The filing explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and not "filed" for purposes of Section 18 of the Exchange Act, limiting its incorporation by reference in other filings.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2025 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Confirm any updates to clinical trial timelines or regulatory milestones mentioned in the corporate update.
- Check for any new debt instruments or equity financing activities not detailed in this 8-K cover page.